For example, vascular endothelial growth factor (VEGF) inhibitors, such as bevacizumab, sorafenib, and sunitinib, are targeted agents designed to reduce blood flow to a tumor by blocking its angiogenesis. The gene discussed is VEGFA; the disease is neoplasm.